346: Zealand's obesity strategy and Immunovant's curious development plan
The Readout Loud
Immunivant's Strategic Shift After Phase Three Success
This chapter explores the recent phase three trial results for Immunivant's autoimmune drug beta-climab, targeting myasthenia gravis. Despite promising outcomes, the company opts to pursue a safer successor drug, while also examining market valuations compared to a rival biotech firm.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
